Recipharm makes major investment to expand US sterile manufacturing footprint

2026-06-16T10:59:00

Fully automatic filling and sealing machine for the production of medicines in ampules.

Source:

Decision strengthens the CMDO’s fill-finish operations and increases capacity for biologics and advanced therapies.

Recipharm is bolstering its US operations through a new multi-million-dollar investment, set to expand its fill and finish capabilities for sterile manufacturing.

It not only strengthens the firm’s capacity to support production of biologics and advanced therapies across the product lifecycle but also help to accelerate development timelines.

Greg Behar, CEO of the CDMO, said: “The demand for biologics and advanced therapies continues to…

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member